Egetis Therapeutics
Rare-disease biopharmaceutical company developing and commercializing therapies for serious conditions with significant unmet need. Its lead medicine, Emcitate (tiratricol), is approved in the United States and European Union for MCT8 deficiency.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Selected patent records
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/egetis-therapeutics/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.